Diabetes therapy trials with inhaled insulin

Expert Opinion on Investigational Drugs

Volumn 15, Issue 7, 2006, Pages 743-762

  Fineberg, Samuel Edwin ^a,b  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b University of Alabama at Birmingham   (United States)

Author keywords

AERx iDMS ; Aradigm ; Eli lilly alkermes; Exubera ; Inhale ; Inhaled insulin; Novo nordisk; Pulmonary insulin; Technosphere

Indexed keywords

GLYCOSYLATED HEMOGLOBIN; INSULIN; INSULIN ANTIBODY; MICROSPHERE; NEW DRUG; RECOMBINANT PROTEIN;

ADULT; AEROSOL; ANIMAL; BIOAVAILABILITY; BIOSYNTHESIS; CHEMICALLY INDUCED DISORDER; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; DIABETES MELLITUS; DRUG FORMULATION; FEMALE; GLUCOSE BLOOD LEVEL; GUINEA PIG; HUMAN; HYPOGLYCEMIA; INHALATIONAL DRUG ADMINISTRATION; INSULIN DEPENDENT DIABETES MELLITUS; LUNG; MALE; METERED DOSE INHALER; MIDDLE AGED; MULTICENTER STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; PHASE 3 CLINICAL TRIAL; PHYSIOLOGY; POWDER; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; RAT; REVIEW;

ADMINISTRATION, INHALATION; ADULT; AEROSOLS; ANIMALS; BIOLOGICAL AVAILABILITY; BLOOD GLUCOSE; CLINICAL TRIALS, PHASE III; DIABETES MELLITUS; DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; DRUG COMPOUNDING; DRUGS, INVESTIGATIONAL; FEMALE; GUINEA PIGS; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIA; INSULIN; INSULIN ANTIBODIES; LUNG; MALE; METERED DOSE INHALERS; MICROSPHERES; MIDDLE AGED; MULTICENTER STUDIES; POWDERS; PROSPECTIVE STUDIES; RANDOMIZED CONTROLLED TRIALS; RATS; RECOMBINANT PROTEINS;

EID: 33747190354     PISSN: 13543784     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543784.15.7.743     Document Type: Review

References (82)

1. TURNER R: The UK Prospective Diabetes Study. A review. Diabetes Care (1998) 21(12 Suppl. 3):C35-C38. •• The late Robert Turner directed and presented the results of the UKPDS study. This is an inclusive review of the trial and its results. These data are very important in the current views of the effectiveness and value of glycaemic control in Type 2 diabetes.
2. DIABETES CONTROL AND COMPLICATIONS TRIAL GROUP: The effect of intensive treatment of diabetes on the development and progression of long term complications. N. Engl. J. Med. (1993) 329(14):977-986. •• This is the first of many DCCT publications that have established the value of intensive glycaemic control in patients with Type 1 diabetes mellitus.
3. HOME P: Contributions of basal and post-prandial hyperglycaemia to micro- and macrovascular complications in people with Type 2 diabetes. Curr. Med. Res. Opin. (2005) 21(7):989-998. •• Evidence is presented that control of post meal hyperglycaemia is highly correlated with cardiovascular mortality and morbidity, and that therapy specifically targeting this period may be uniquely beneficial in preventing the long-term complications of diabetes.
4. KORYTKOWSKI M: When oral agents fail; practical barriers to starting insulin. Int. J. Obes. (2002) 26(Suppl. 3):S18-S24. • This paper discusses the barriers that delay the initiation of insulin in patients who are failing their initial oral therapies.
5. GANSSLEN M: Uber inhalation von insulin. Klin. Wochensubcutaeoushr. (1925) 4:71. • This is the earliest report of insulin inhalation therapy.
6. PATTON JS, NAGARAJAN S: Inhaled insulin. Adv. Drug Deliv. Rev. (1999) 135(2-3):235-247. • John Patton is the inventor of the Exubera system. This is a good review of the technicalities of insulin inhalation.
7. BYRON PR: Drug delivery via the respiratory tract. J. Aerosol Med. (1994) 7(1):49-75. •• Byron presents an inclusive review of drug delivery via the respiratory tract.
8. SCHUSTER J, LLOYD RR, LLOYD P: The AERx aerosol delivery system. J. Pharm. Res. (1997) 14(3):354-357. • This is an excellent review of the development and principles underlying this aerosol system.
9. ANONYMOUS: Insulin inhalation: NN 1998. Drugs RD (2004) 5(1):46-49. • This is a progress report of the Novo liquid insulin programme.
10. BRUNNER G, BALENT B, ELLMERER M et al.: Dose-response relation of liquid aerosol inhaled insulin in Type I diabetic patients. Diabetologia (2001) 44(3):305-308. • This paper discusses the inhalation of liquid aerosol insulin using the AERx system.
11. AN B, REINHARDT RR: Effects of different durations of breath holding after inhalation of insulin using the AERx insulin diabetes management system. Clin. Ther. (2003) 25:2233-2244. (Pubitemid 37076316)
12. BRUNNER G, BALENT B, ELLMERER M et al.: Dose-response relation of liquid aerosol inhaled insulin in Type I diabetic patients. Diabetologia (2001) 44(3):305-308. (Pubitemid 32234455)
13. HIMMELMANN A, JENDLE J, MELLEN A, PETERSEN AH, DAHL UL, WOLLMER P: The impact of smoking on inhaled insulin. Diabetes Care (2003) 26(3):677-682. •• A major issue facing the developers of inhaled insulin is dealing with the effects of smoking on insulin absorption.
14. HENRY RR, CHU MS, KIM N et al.: Young and elderly Type 2 diabetic patients inhaling insulin with the AERx insulin diabetes management system: a pharmacokinetic and pharmacodynamic comparison. J. Clin. Pharmacol. (2003) 43(11):1228-1234. •• Henry et al. have conducted a trial demonstrating minor differences if the effects of inhaled insulin in older and younger patients who have Type 2 diabetes. (Pubitemid 37280794)
15. HENRY RR, HOWLAND WC III, CHU N, KIM D, AN B, REINHARDT RR: Inhaled insulin using the AERx Insulin Diabetes Management System in healthy and asthmatic subjects. Diabetes Care (2003) 26(3):764-769. •• A vital issue that faces the developers of inhaled insulin is the effects of insulin inhalation in impaired lungs, such as in individuals with asthma, chronic obstructive pulmonary disease and in individuals with an acute respiratory illness. This is an excellent trial in non diabetic individuals with and without asthma.
16. McELDUFF A, KAM PC, CLAUSON P: Influence of acute respiratory tract infection on the absorption of inhaled insulin using the AERx insulin Diabetes Management System. Br. J. Clin. Pharmacol. (2005) 59(5):546-551. • A trial in healthy individuals during and after recovery from an acute respiratory infection is presented. (Pubitemid 40632245)
17. KAPITZA C, HOMPESCH M, SCHARLING B, HEISE T: Intrasubject variability of inhaled insulin in Type 1 diabetes: a comparison with subcutaneous insulin. Diabetes Technol. Ther. (2004) 6(4):466-472. (Pubitemid 39121371)
18. HERMANSEN K, PETERSEN AH, BELLAIRE S, ADAMSON U: Intensive therapy with inhaled insulin via the AERx insulin diabetes management system: a 12 week proof of concept trial in patients with Type 2 diabetes. Diabetes Care (2004) 27(1):162-167. (Pubitemid 38196726)
19. OSBORNE R: Novo Nordisk agrees to $55 M for Aradigm's insulin program. BioWorld Today (2004) 15(189):1-2.
20. DUNBAR C, SOMMERER K, DE LONG M, VERMA A, BATYCKY R: In vitro and in vivo dose delivery characteristics of large porous particles for inhalation. Int. J. Pharmaceutics (2002) 245:179-189. • A discussion of the merits of large particle delivery to the lung is presented. Such particles are the basis for the Lilly/Alkermes insulin delivery system.
21. WOLFF RK, WROBLEWSKI VJ, ENGELHARDT JA, DEAVER DR, SHAW ME: 13-week inhalation study to characterize the toxicity and PK/PD of a human inhaled insulin powder (HIIP) in beagle dogs. Diabetes (2004) 53(6 Suppl. 2):A115-A116. • This is a nice discussion of the toxicological studies done in the Lilly/Alkermes inhaled insulin programme.
22. DE LONG M, DAWSON M, MEYER T, SOMMERER K, DUNBAR C: Dose delivery characteristics of the AIR® pulmonary delivery system over a range of inspiratory flow rates. J. Aerosol Med. (2005) 18(4):452-459. •• This is a nice discussion of the effects of air flow on insulin delivery using the AIR system.
23. RAVE K, DE LA PENA A, SEGER M, HEINEMANN L, BATYCKY R, MUCHMORE D: Dose-response and dose equivalency of human insulin inhalation powder (HIIP) using the Lilly/Alkermes inhaled insulin system compared to subcutaneous (SC) insulin Lispro. Diabetes (2005) 54(6 Suppl. 1):A89.
24. RAVE KM, DE LA PENA A, SEGER M et al.: Dose-response of inhaled dry-powder insulin and dose equivalence to subcutaneous insulin lispro. Diabetes Care (2005) 28(10):2400-2405. •• This is a beautifully carried out dose-response study using the Lilly/Alkermes insulin powder.
25. GARG S, MUCHMORE D, DE LA PENA A, SUN B, SILVERMAN B: Safety and efficacy of preprandial human insulin inhalation powder (HIIP) delivered by the Lilly/Alkermes inhaled insulin system versus injectable insulin in patients with Type 1 diabetes (T1D). Diabetes (2005) 54(6 Suppl. 1):A89.
26. ROSENSTOCK J, DE LA PENA A, SUN B, SILVERMAN B: The safety and efficacy of human insulin powder HIIP) versus injectable insulin in patients with Type 1 diabetes (T1D). Diabetologia (2005) 48(Suppl. 1):A30. (Pubitemid 40434505)
27. SKYLER JS, KOURIDES IA, LANDSCHULZ WH, BALAGTAS CC, CHENG SL, GELFAND RA: Efficacy of inhaled human insulin in Type 1 diabetes mellitus: a randomized proof-of-concept study. Lancet (2001) 357(9253):331-335. • This is the earliest published report of a trial using the Exubera system. (Pubitemid 32128537)
28. WHITE S, CHEU S, CONLEY PW et al.: Exubera: pharmaceutical development of a novel product for pulmonary delivery of insulin. Diabetes Technol. Ther. (2005) 7(12):896-906. •• In a very informative article, White et al. discuss in detail the issues involved in the development of Exubera. (Pubitemid 43133996)
29. RAVE K, HEINEMANN L, SHA S, BECKER RH, WILLAVIZE SA, HEISE T: Time-action profile of inhaled insulin in comparison with subcutaneously injected insulin lispro and regular human insulin. Diabetes Care (2005) 28(5):1077-1082. •• This is a very fine study of the kinetics of pulmonary insulin contrasted with subcutaneous insulin.
30. EDGERTON DS, SCOTT M, BOWEN L et al.: Inhalation of insulin (Exubera) is associated with augmented disposal of portally infused glucose in dogs. Diabetes (2005) 54(4):1164-1170. • Edgerton et al. explore the hepatic versus peripheral activity of inhaled insulin in an awake dog model system. (Pubitemid 40446332)
31. FINEBERG SE, FINCO-KENT D, LIU C, KRASNER A: Antibody response to inhaled insulin in patients with Type 1 or Type 2 diabetes. An analysis of initial Phase II and III inhale insulin (Exubera) trials and a two-year extension trial. J. Clin. Endocrinol. Metab. (2005) 90(6):3287-3294. •• Fineberg et al. show immunogenicity data from short and long term trials of Exubera and present evidence that insulin antibodies have no clinical impact in inhaled insulin treated patients. (Pubitemid 41014288)
32. HEISE T, TYDEK C, STEPHAN JA et al.: The effect of insulin antibodies on the metabolic action of inhaled and subcutaneous insulin: a prospective randomized pharmacodynamic study. Diabetes Care (2005) 28(9):2161-2169. •• Heise et al. prospectively studied patients who developed insulin antibodies and showed that no metabolic effects on insulin action could be shown. (Pubitemid 41242462)
33. SKYLER JS, RASKIN P, YALE JF, BARRETT E, GERICH JE, GERSTEIN HC: Inhaled Insulin Phase III Type 1 Diabetes Study Group: use of inhaled insulin in a basal/bolus regimen in Type 1 subjects: a 6-month, randomized, comparative trial. Diabetes Care (2005) 28(7):1630-1635. (Pubitemid 40923076)
34. DEFRONZO RA, CEFALU WT, PULLMAN J, LERMANN S, BODE BW, PHILLIPS LS: Exubera Phase III Study Group: efficacy of inhaled insulin in patients with Type 2 diabetes not controlled with diet and exercise: a 12-week, randomized, comparative trial. Diabetes Care (2005) 28(8):1922-1928. (Pubitemid 41060964)
35. ROSENSTOCK J, MURPHY LJ, CLEMENT SC et al.: Inhaled insulin improves glycemic control when substituted for or added to oral combination therapy in Type 2 diabetes: a randomized controlled trial. Ann. Intern. Med. (2005) 143(18):549-558. (Pubitemid 41476551)
36. HOLLANDER PA, TOWE R, MEHTA AE et al.: Efficacy and safety of inhaled insulin (Exubera) compared with subcutaneous insulin therapy in patients with Type 2 diabetes: results of a 6-month, randomized, comparative trial. Diabetes Care (2004) 27(10):2356-2362. (Pubitemid 39281385)
37. FREEMANTLE N, DUHOT D, HOMPESCH M et al.: Availability of inhaled insulin promotes greater perceived acceptance of insulin therapy in patients with Type 2 diabetes. Diabetes Care (2005) 28(2):427-428. • An important issue in the development of inhaled insulin systems, is whether patients would prefer inhaled insulin over that of injected insulin. This brief article reviews this topic.
38. ROSENSTOCK J, BOLINDER B, GERBER RA: Patient satisfaction and glycemic control after 1 year with inhaled insulin (Exubera) in patients with Type 1 or Type 2 diabetes. Diabetes Care (2004) 27(6):1318-1323. • In actual long-term use, patients were satisfied with the Exubera system.
39. DUMAS R, RIESE RJ, TEETER JG: Exubera® is well tolerated and achieves tight glycemic control in patients with Type 1 diabetes. Diabetes (2005) 54(Suppl. 1):A87.
40. DUMAS R, RIESE RJ: TEETER J G: Inhaled insulin (Exubera™) achieves tight glycemic control and is well tolerated in patients with Type 1 diabetes. Diabetologia (2005) 48(Suppl. 1):A30.
41. CEFALU WT: Long-term use of Exubera® in Type 2 diabetes: observations on glycemic control, pulmonary function and antibody formation. Diabetes (2005) 54(Suppl. 1):A88.
42. LABIRIS R, KAWABATA T, SADRZADEH N et al.: Validation of radiolabelled insulin powder for Exubera® studies. Diabetes (2005) 54:A106.
43. TESTA MA, HAYES JF, SCRANTON RE, SIMONSON DC: An international trial of sulfonylurea plus either metformin or Exubera: impact on quality of life and treatment satisfaction. Diabetologia (2004) 47(Suppl. 1):A5.
44. SIMONSON DC, HAYES JF, SCRANTON RE, TESTA MA: Improving quality of life in Type 2 diabetes when Exubera is added after failure on metformin: a multicenter, international trial. Diabetologia (2004) 47(Suppl. 1):A311.
45. SKYLER JS: Long term efficacy, and safety of inhaled insulin after 4 years of continuous therapy. Diabetologia (2004) 47(Suppl. 1):A311.
46. DEFRONZO RA: Efficacy and safety of inhaled insulin (Exubera) compared with rosiglitazone in Type 2 diabetes patients not optimally controlled on diet and exercise, randomized, comparative trial. Diabetes (2003) 52(Suppl. 1):A38.
47. BECKER R, FRICKE SS, PIECHATZEK A: The effect of smoking cessation and subsequent resumption on absorption of inhaled insulin (Exubera). Diabetes (2003) 52(6 Suppl. 1):A37.
48. STEINER S, WILSON BR, HARZER O, HEINEMANN L, RAVE K: Technosphere/ insulin-proof of concept study with a new insulin formulation for pulmonary delivery. Exp. Clin. Endocrinol Diabetes (2002) 110(1):17-21. • Technosphere insulin particles are produced by a process very different from Exubera oar the Lilly/Alkermes insulins. The development of these particles is reviewed.
49. BOSS AH, CHEATHAM WW, TIM H: Inhaled technosphere/insulin: glucose elimination at the right time? Diabetes (2005) 54(6 Suppl. 1):A109.
50. BOSS AH, RAVE K, CHEATHAM WW: The variability and time-action profile of inhaled technosphere/insulin compares favorably to that of subcutaneous human regular insulin. Diabetes (2005) 54(6 Suppl. 1):A88.
51. BOSS A, CHEATHAM W: Mimicry of the early phase insulin response in humans with rapidly available inhaled insulin accelerates postprandial glucose disposal compared to slower bioavailable insulin. Diabetes (2005) 54(6 Suppl.1):A333.
52. LAUREANO RT, CARBALLO I, ROUSSEAU K et al.: rapid absorption and clearance of insulin from the lung following pulmonary administration of technosphere/insulin; a pharmacokinetic study in a rat model. Diabetes (2005) 54(6 Suppl. 1):A110.
53. KRUEGER P, LEINER KA, CARBALLO I, HARRIS E, WOODS R, GELBER C: Toxicological profile of pulmonary drug delivery agent. Diabetes (2004) 53(6 Suppl. 2):A110.
54. LEINER KA, DAUKAS K, MENKIN P et al.: The pharmacokinetic profile of insulin administered by inhalation in the rat. Diabetes (2004) 53(6 Suppl. 2):A111.
55. ROSENSTOCK J, RIVERA-SCHAUB T, OTTERBACH K et al.: A randomized, double-blind, placebo controlled study of the efficacy and safety of inhaled technosphere insulin in patients with Type 2 diabetes (T2DM). Diabetes (2005) 54(6 Suppl. 1):A88. (Pubitemid 41476551)
56. CHEATHAM WW, BOSS AH, FORST T, PFÜTZNER A: A novel pulmonary insulin formulation replicates first phase insulin release and reduces s-proinsulin levels. Diabetes (2004) 53(6 Suppl. 2):A107.
57. PFUETZNER A, MEYER T, HAUSSERMANN S et al.: Lung distribution of radiolabelled technosphere/insulin. Diabetes (2003) 52(6 Suppl. 1):A107.
58. HAUSMANN M, HEINEMANN L, BUCHWALD A, HEISE T: Add-on therapy with Kos inhaled insulin using a metered dose inhaler is as efficacious as add-on therapy with Lantus® in poorly controlled Type 2 diabetic patients treated with sulfonylurea or metformin. Diabetes (2005) 54(6 Suppl. 1):A102-A103.
59. HAUSMANN M, HEINEMANN L, BUCHWALD A, HEISE T: Add-on therapy with Kos inhaled insulin using a metered dose inhaler is as efficacious as add-on therapy with Lantus® in poorly controlled Type 2 diabetic patients treated with sulfonylurea or metformin. Diabetologia (2005) 48(Suppl. 1):A297.
60. LI J, WONG S, LEUNG E, SU SL: Alveair™, a new pulmonary insulin-its glucose responses compared to Aspar insulin intravenous injection in normal rats and its insulin profile in guinea pigs. Diabetes (2005) 54(6 Suppl. 1):A112.
61. LEUNG FK, LI J, LEUNG E: Dose-response of Alveair Insulin in normal rats-a new pulmonary insulin formulation. Diabetes (2004) 53(6 Suppl. 1):A468.
62. LEUNG FK, LI J, LEUNG E, LIU N: Insulin pharmacokinetic estimates of Alveair® - anew pulmonary insulin formulation. Diabetes (2005) 54(6 Suppl. 1):A467-A468.
63. LEUNG FK, LIN CC, WONG S et al.: Alveair® , a new pulmonary insulin -its first human trial and the preclinical animal data correlation. Diabetes (2004) 53(6 Suppl. 2):A111.
64. HSIA CCW, RASKIN P: The diabetic lung: relevance of alveolar microangiopathy for the use of inhaled insulin. Am. J. Med. (2005) 118:205-211. •• Hsia and Raskin present an concise review of the pulmonary safety issues regarding insulin inhalation.
65. SKYLER JS: WEINSTOCK, RUTH S et al.: The Inhaled Insulin Phase III Type 1 Diabetes Study Group: use of inhaled insulin in a basal/bolus insulin regimen in Type 1 diabetic subjects: a 6-month, randomized, comparative trial. Diabetes Care (2005) 28(7):1630-1635. •• This is a report of a 6-month trial of Exubera in Type 1 patients contrasted with a subcutaneous insulin comparator.
66. SADRI H, MacKEIGAN LD, LEITER LA, FINARSON TR: Willingness to pay for inhaled insulin: a contingent valuation approach. Parmacoeconomics (2005) 23(12):1215-1227. •• Another vital issue in the development of inhaled insulin systems is the willingness of patients and third-party payers to pay for this more expensive mode of insulin delivery. This paper uses economic modelling to examine this topic.
67. http://clinicaltrials.gov/ct/show/NCT00127634?order=1 Trial NCT00127634.
68. http://clinicaltrials.gov/ct/show/NCT00157339?order=1 Trial NCT00157339.
69. http://clinicaltrials.gov/ct/show/NCT00099515?order=1 Trial NCT00099515.
70. http://clinicaltrials.gov/ct/show/NCT00063128?order=1 Trial NCT00063128.
71. http://clinicaltrials.gov/ct/show/NCT 00139659?order=1 Trial NCT00139659.
72. http://clinicaltrials.gov/ct/show/NCT 00138671?order=1 Trial NCT00138671.
73. http://clinicaltrials.gov/ct/show/NCT00246623?order=1 Trial NCT00246623.
74. http://clinicaltrials.gov/ct/show/NCT00143104?order=1 Trial NCT00143104.
75. http://clinicaltrials.gov/ct/show/NCT00143338?order=1 Trial NCT00143338.
76. http://clinicaltrials.gov/ct/show/NCT00136916?order=1 Trial NCT00136916.
77. http://clinicaltrials.gov/ct/show/NCT00134147?order=1 Trial NCT00134147.
78. http://clinicaltrials.gov/ct/show/NCT00139763?order=1 Trial NCT00139763.
79. http://clinicaltrials.gov/ct/show/NCT00143247?order=1 Trial NCT00143247.
80. http://clinicaltrials.gov/ct/show/NCT00150410?order=1 Trial NCT00150410.
81. http://www.clinicaltrials.gov/ct/show/NCT00143247?order=1 Trial NCT00143247.
82. http://www.clinicaltrials.gov/ct/show/NCT00150410?order=1 Trial NCT00150410.